| Literature DB >> 33579329 |
Tian Zhou1,2, Zenan Yuan3, Jianyu Weng1, Duanqing Pei4, Xin Du5, Chang He6, Peilong Lai7.
Abstract
Mesenchymal stromal cells (MSCs), also known as mesenchymal stem cells, have been intensely investigated for clinical applications within the last decades. However, the majority of registered clinical trials applying MSC therapy for diverse human diseases have fallen short of expectations, despite the encouraging pre-clinical outcomes in varied animal disease models. This can be attributable to inconsistent criteria for MSCs identity across studies and their inherited heterogeneity. Nowadays, with the emergence of advanced biological techniques and substantial improvements in bio-engineered materials, strategies have been developed to overcome clinical challenges in MSC application. Here in this review, we will discuss the major challenges of MSC therapies in clinical application, the factors impacting the diversity of MSCs, the potential approaches that modify MSC products with the highest therapeutic potential, and finally the usage of MSCs for COVID-19 pandemic disease.Entities:
Keywords: Artificial intelligence (AI); COVID-19; Clinical applications; Extracellular vesicles; Heterogeneity; Mesenchymal stromal cells
Mesh:
Year: 2021 PMID: 33579329 PMCID: PMC7880217 DOI: 10.1186/s13045-021-01037-x
Source DB: PubMed Journal: J Hematol Oncol ISSN: 1756-8722 Impact factor: 17.388